Form 4: Olema Pharma Officer Sells Shares After Option Exercise
Insider Transaction Report
Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, exercised stock options and subsequently sold a significant number of common shares.
Summary
- David C. Myles, Chief Discovery & Non-Clinical Development Officer at Olema Pharmaceuticals, Inc. (OLMA), reported multiple transactions involving company stock.
- On January 13, 2026, Myles exercised options to acquire 50,000 shares of common stock at an exercise price of $4.87 per share.
- On January 14, 2026, Myles exercised options to acquire an additional 50,000 shares of common stock, also at an exercise price of $4.87 per share.
- Following these exercises, Myles sold a total of 100,000 shares of common stock across several transactions between January 12 and January 14, 2026.
- The sale prices for these transactions ranged from $27.35 to $29.39, with weighted average prices for the reported sales being $28.34, $27.60, $28.49, $28.60, and $28.99.
- After these transactions, Myles directly beneficially owns 542,761 shares and indirectly owns 144,846 shares through Myles Properties Inc. and 12,831 shares through The Myles Family Revocable Inter Vivos Trust.
- A previous Form 4 filed on December 23, 2025, contained a scrivener's error that overstated direct beneficial ownership by 120 shares, which has been corrected in this filing.
Sentiment
Score: 4
Explanation: The sentiment is moderately negative due to significant insider selling by a key executive, even though it follows option exercises. While the exercises themselves are positive for the executive, the subsequent large-scale sales can be interpreted by the market as a lack of conviction or a move to diversify, potentially putting downward pressure on the stock.
Positives
- The officer exercised stock options at a significantly lower price ($4.87) compared to the market sale prices (ranging from $27.35 to $29.39), indicating a substantial personal gain from the equity compensation.
Negatives
- A significant number of shares (100,000) were sold by a key executive, which could be interpreted negatively by the market as a reduction in insider holdings.
Future Outlook
The filing details a vesting schedule for stock options, with 25% vesting on February 1, 2024, and 1/48 of the total shares vesting each month thereafter, contingent on continuous service.
Industry Context
This Form 4 filing reflects routine insider transaction activity within the biotechnology sector, where executive compensation often includes stock options that are exercised and sold for liquidity or portfolio diversification. Such transactions are common and typically driven by personal financial planning rather than specific company news.
Comparison to Industry Standards
- Insider selling, particularly after option exercises, is a common practice across industries, including biotechnology. While the volume of sales (100,000 shares) is notable for an individual executive, it is not unusual for officers to monetize vested equity.
- Without specific company or peer group benchmarks for executive sales, it is difficult to assess if this volume is above or below typical levels for a company of Olema Pharmaceuticals' size and stage. For example, executives at similar-sized biotech firms like Mirati Therapeutics or Relay Therapeutics have also reported significant option exercises and sales in the past, often driven by personal financial planning rather than a specific negative outlook on the company.
Related Party Transactions
- Shares are indirectly held by Myles Properties Inc., of which the Reporting Person is President.
- Shares are indirectly held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
Stakeholder Impact
- Shareholders: The sale of a significant number of shares by a key executive could be perceived negatively, potentially leading to a decrease in investor confidence or downward pressure on the stock price.
- Employees: No direct impact on employees is mentioned, but executive share sales can sometimes affect internal morale if interpreted as a lack of long-term commitment.
Next Steps
- Continued monthly vesting of remaining stock options (1/48 of total shares each month after February 1, 2024), subject to continuous service.
Key Dates
| Date | Description |
|---|---|
| 2024-02-01 | First vesting date for 25% of shares subject to stock options. |
| 2025-12-23 | Date of previous Form 4 filing containing a scrivener's error. |
| 2026-01-12 | Date of first reported common stock sale by David C. Myles. |
| 2026-01-13 | Date of first reported stock option exercise and subsequent common stock sales by David C. Myles. |
| 2026-01-14 | Date of second reported stock option exercise and subsequent common stock sales by David C. Myles, and filing date of this Form 4. |
| 2033-01-31 | Expiration date for exercised stock options. |
Recommendation
holdWhile the insider selling by a key executive after exercising options is a negative signal, it's a common practice for executives to monetize vested equity for personal financial planning. The sales occurred at prices significantly higher than the exercise price, indicating a profitable transaction for the insider. Without additional context on company performance or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future insider activity and company developments rather than making an immediate 'buy' or 'sell' decision based solely on this Form 4.
Keywords
Olema Pharmaceuticals, OLMA, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.